Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C difficile Education & Advocacy, explained how FDA-approved microbiome-based therapeutics help to treat and prevent C difficile infection.
Amid National C. Diff Awareness Month, Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy (PLF), explains how recent FDA-approved microbiome-based therapeutics help to treat and prevent infection from Clostridioides difficile.
PLF, which was founded in response to the death of 56-year-old Peggy Lillis from an infection caused by C difficile, is the leading national organization dedicated to combating C difficile infections by educating the public, shaping policy, and empowering advocates.
Transcript
How has the FDA approval of microbiome-based therapeutics impacted C difficile treatment and prevention?
It's early. The first one that got approved became available in January, so it's been 10 or 11 months; the other one became available in June. We are seeing some really optimistic signs. I think the most important thing for C diff patients, our community, and our movement is that it had been 12 years since any new treatment for C diff had been approved by the FDA. And so, the approval of not just 1, but 2 new treatments, which were a completely new paradigm for treating this disease and preventing recurrence, I think has really restored hope for a lot of us and made us think fighting for the past 20 years has been worth it, and feeling like we're going to get to a place where people don't suffer.
What we really want to change with these new therapies, or preventatives, is when patients are battling recurrent C diff, often they're given endless rounds of antibiotics. You might get vancomycin, and then you fail vancomycin, or vancomycin fails you, I should say. Then you're put on a vancomycin taper, and that doesn't work. So then you're given fidaxomicin. So, at this point, we're talking you've been sick for 2 months already. If you're somebody who works and has a family, that's incredibly disruptive. Then, for a time, people were getting a fecal microbiota transplant [FMT], or a stool transplant. But the FDA always considered that experimental, so it really limited the number of people that were able to access that; there's probably about 180,000 people who get recurrent C diff every year, and maybe 10% or 20% of them were able to access an FMT. So, now that we have FDA-approved products, what we hope is that everyone will get that preventative to stop them from getting a recurrence.
I think they're also beginning to not just help people who are getting them right now, but also beginning to change practice guidelines. Prior to this, the standard was the antibiotics had to fail 3 times before you'd even be considered for an FMT. Again, depending on the exact prescription, it could be weeks or months of you suffering before you were offered this sort of treatment of last resort with a fecal transplant. What we hope is that with these new therapeutics, you will get this microbiome intervention way sooner, and so you'll have less physical and socioemotional damage than patients that didn't have access to these therapies.
There's definitely been a little bit of sticker shock. These therapies, they are expensive compared to what has been the previous regime, but by interrupting the cycle of recurrence, they will ultimately save us money. The average cost of somebody who's dealing with multiply recurrent C diff, for their treatment is around $40,000. What we ideally would like to see is that when a patient tests positive for C diff that they're given a narrow spectrum of antibiotic to sort of limit the further disruption of their microbiome. Then, if they get a recurrence—and, even with the best antibiotic we have now, about 10% to 15% will—they will then get a microbiome restoration preventative after that first recurrence to hopefully prevent further occurrences.
Another reason why that's really important is because what we know, and there was a recent article about this that came out a few months ago, is that for every time somebody recurs, their chances of recurrence increases. So, you get C diff, you get treated, you have a 20% chance of recurring. You get that recurrence, now you have a 40% chance of recurring. You get a second recurrence, it's a 60% chance of recurring.
Along with that, what we've seen is that every time a person recurs, their chances of going into septic shock increases, their chances of needing a colectomy increase, and their chances of death increase. Of course, all of those treatment interventions after the first recurrence are more and more costly to the patient and to the health care system. So, I feel like by interrupting this, not letting anybody get past a first recurrence, it will drastically improve people's experiences with C diff and also ultimately save us money and resources.
Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma
May 15th 2024Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Panel Addresses Minority Physician Shortage, Maternal Health, at Senate Committee Hearing
May 15th 2024The senate hearing held by the US Senate Committee on Health, Education, Labor, and Pensions, led by Sen. Bernie Sanders (I, Vermont), chairman of the committee, and ranking member Sen. Bill Cassidy, MD, (R, Louisiana), addressed the critical issue of physician and health care worker shortages, as well as the maternal health crisis, in the US.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
CAR T Proves Effective and Safe for Refractory Multiple Myeloma
May 15th 2024Due to increasing reports of multiple myeloma and the emergence of chimeric antigen receptor (CAR) T-cell therapy as a treatment option, these investigators conducted a comprehensive review of the medical literature on the latest CAR T developments in the MM space.
Read More
Patients With MG Report Higher Azathioprine Discontinuation vs Other Immunosuppressants
May 15th 2024Survey data from over 200 patients showed that treatment discontinuation was lower for those taking mycophenolate or methotrexate than for those taking azathioprine for their myasthenia gravis (MG).
Read More